Silverarc Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Silverarc Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-466,345	Closed	-$18.5M	–	80
2026 Q1	$18.5M	Buy	466,345 +8,142	+2%	+$208K	1.89%	18
2025 Q4	$11.5M	Buy	458,203 +316,965	+224%	+$8.03M	1.59%	20
2025 Q3	$3.43M	Buy	141,238 +136,238	+2,725%	+$2.42M	0.46%	52
2025 Q2	$65.7K	Sell	5,000 -227,758	-98%	-$2.89M	0.01%	63
2025 Q1	$3.35M	Sell	232,758 -366,194	-61%	-$5.99M	0.68%	39
2024 Q4	$10M	Sell	598,952 -145,640	-20%	-$2.41M	2.19%	14
2024 Q3	$11.9M	Buy	+744,592	New	+$9.12M	2.67%	11

Silverarc Capital Management's CNTA Position: Q2 2026 in Review

Silverarc Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 466,345 shares — an estimated $18.5M sold.

Silverarc Capital Management first reported a position in CNTA in Q3 2024 and held it in 7 quarters. The position peaked at $18.5M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Silverarc Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Silverarc Capital Management sold 466,345 Centessa Pharmaceuticals shares in Q2 2026, an estimated $18.5M.
Silverarc Capital Management first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 7 quarters.
Silverarc Capital Management's Centessa Pharmaceuticals position peaked at $18.5M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.